Assenagon Asset Management’s Novavax NVAX Stock Holding History

Assenagon Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-364,770	Closed	-$2.97M	–	1229
2026 Q1	$2.97M	Buy	+364,770	New	+$3.31M	﹤0.01%	704

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Assenagon Asset Management's NVAX Position: Q2 2026 in Review

Assenagon Asset Management sold out of Novavax (NVAX) in Q2 2026, closing a stake of 364,770 shares — an estimated $2.97M sold.

Assenagon Asset Management first reported a position in NVAX in Q1 2026 and held it in 1 quarter. The position peaked at $2.97M in Q1 2026. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Assenagon Asset Management reported no remaining Novavax position as of Q2 2026 after selling out during the quarter.
Assenagon Asset Management sold 364,770 Novavax shares in Q2 2026, an estimated $2.97M.
Assenagon Asset Management first reported a position in Novavax in Q1 2026 and held it in 1 quarter.
Assenagon Asset Management's Novavax position peaked at $2.97M in Q1 2026.
266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.